Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study

CONCLUSIONS: Based on the above findings, we hypothesize that anti-CGRP Mabs did not influence neuronal and vascular events related to cortical spreading depression (CSD) which is considered the pathophysiological substrate of aura. Conversely, these antibodies are able to counteract, via their peripheral mechanisms of action, the sensitization of the trigemino-vascular pathway which is triggered by CSD. This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent.PMID:38332541 | PMC:PMC10853579 | DOI:10.1111/cns.14595
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Source Type: research